The standard of care for HER2-positive breast cancers includes surgical resection and adjuvant trastuzumab combined with chemotherapy as first-line therapy, followed by trastuzumab-emtansine conjugate as second-line therapy [5,6,7]. The gene discussed is ERBB2; the disease is breast carcinoma.